← Scroll for more →
X4 Pharmaceuticals, Inc (XFOR)
Biological Products, (No Diagnostic Substances)
Latest Price
$3.35
TTM P/E
2.64
Normalized P/E
--
TTM Div Yield
--
Fwd Div Yield
--
Book Value
1.65
P/B Ratio
2.03
Institutional Ownership
100.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Morgan Stanley | 9.46M | $44.0M | 9.84% | -5.7K | 2026-06-30 |
| FMR LLC | 8.32M | $38.0M | 8.66% | +218.3K | 2026-06-30 |
| Bain Capital Life Sciences Investors, LLC | 7.97M | $37.0M | 8.29% | -- | 2026-06-30 |
| Perceptive Advisors LLC | 7.93M | $37.0M | 8.25% | +1.20M | 2026-06-30 |
| Saturn V Capital Management LP | 6.97M | $32.0M | 7.26% | +516.7K | 2026-06-30 |
| Empery Asset Management, LP | 6.93M | $32.0M | 7.21% | -2.01M | 2026-06-30 |
| Deep Track Capital, LP | 5.88M | $27.0M | 6.12% | -460.8K | 2026-06-30 |
| BlackRock, Inc. | 5.55M | $25.0M | 5.78% | +4.34M | 2026-06-30 |
| Kalehua Capital Management LLC | 3.72M | $17.0M | 3.87% | -- | 2026-06-30 |
| Vanguard Capital Management LLC | 3.72M | $17.0M | 3.87% | +218.2K | 2026-06-30 |